Binding Site, based in Birmingham, UK, specializes in the research, development, manufacture and sale of medical diagnostic products focused on Multiple Myeloma and other B-Cell dyscrasias and Primary Immunodeficiency (PID).

With expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff tools to improve diagnosis and management of patients across a range of B-cell cancers and immune system disorders.

Binding Site is currently developing Combylite, which recently presented studies suggest may have applications in non-monoclonal diseases, including chronic kidney disease and liver disease.

Binding Site will also continue to invest in new assays for use on its SPAPLUS analyser, which continues to grow its presence in laboratories worldwide.

Bradwell will retain an ownership interest in the company, and remain on the Board.